Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
43.82
+0.75 (1.74%)
At close: Sep 8, 2026, 4:00 PM EDT
43.98
+0.91 (2.11%)
Pre-market: Sep 9, 2026, 5:32 AM EDT
Edgewise Therapeutics Employees
Edgewise Therapeutics had 127 employees as of June 30, 2026. The number of employees increased by 1 or 0.79% compared to the same quarter last year.
Employees
127
Change
1
Growth
0.79%
Revenue / Employee
n/a
Profits / Employee
-$1,552,929
Market Cap
4.76B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 127 | 1 | 0.79% |
| Mar 31, 2026 | 154 | 37 | 31.62% |
| Dec 31, 2025 | 146 | 36 | 32.73% |
| Sep 30, 2025 | 136 | 28 | 25.93% |
| Jun 30, 2025 | 126 | 29 | 29.90% |
| Mar 31, 2025 | 117 | 25 | 27.17% |
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Sep 30, 2024 | 108 | 28 | 35.00% |
| Jun 30, 2024 | 97 | 23 | 31.08% |
| Mar 31, 2024 | 92 | 25 | 37.31% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Sep 30, 2023 | 80 | 30 | 60.00% |
| Jun 30, 2023 | 74 | 32 | 76.19% |
| Mar 31, 2023 | 67 | 29 | 76.32% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Sep 30, 2022 | 50 | 20 | 66.67% |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Mar 31, 2022 | 38 | 16 | 72.73% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| ACADIA Pharmaceuticals | 798 |
| CRISPR Therapeutics AG | 393 |
| Dyne Therapeutics | 289 |
| Relay Therapeutics | 202 |
| Celcuity | 155 |
| Parabilis Medicines | 145 |
| Definium Therapeutics | 106 |
EWTX News
- 6 days ago - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PRNewsWire
- 15 days ago - Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 - PRNewsWire
- 15 days ago - Edgewise Therapeutics Slides: FY 2026 - Filings
- 19 days ago - Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan - TheFly
- 4 weeks ago - Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs - TheFly
- 4 weeks ago - Edgewise Therapeutics reports Q2 EPS (53c), consensus (47c) - TheFly
- 4 weeks ago - Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - PRNewsWire
- 4 weeks ago - Edgewise Therapeutics Quarterly report: Q2 2026 - Filings